TOT BIOPHARM International Co. Ltd. (1875) AI Stock Analysis

• Market Cap: HK$1.48B
• Dividend Yield: N/A
• Average Volume (3M): 147.41K
• Price to Earnings (P/E): 36.9
• Beta (1Y): 0.53
• Revenue Growth: 38.48%
• EPS Growth: N/A
• Country: HK
• Employees: 611
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 772,787,900
• 10 Day Avg. Volume: 131,120
• 30 Day Avg. Volume: 147,413
• PEG Ratio: 0.33
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.52
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$2.40
• Price Target Upside: 25.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 68 Neutral
• Price Target: ―

TOT BIOPHARM demonstrates resilience with strong financial recovery and a solid balance sheet, although liquidity issues persist. Technical indicators show mixed signals with some upward momentum, but valuation concerns exist with a high P/E ratio and no dividend yield. The overall score reflects these mixed factors, highlighting the need for careful consideration of liquidity and valuation risks.

TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model

Company Description

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. The company's principal drug candidate is TAB008 for the treatment of non-squamous non-small-cell lung cancer metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, and hepatocellular carcinoma. It also offers TOZ309 for malignant brain tumor. Further, the company develops TAA013 for HER2+ breast cancer which is under Phase III clinical trial; TAE020 which is under preclinical trial for acute myeloid leukemia; TAB014 for wet age-related macular degeneration and is under Phase II clinical trial. In addition, it develops TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, non-small-cell lung cancer (NSCLC), and gastric cancer; TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.

How the Company Makes Money

TOT BIOPHARM makes money primarily through the sale of its oncology drugs and therapies. The company's revenue streams include the commercialization of its proprietary biologics and small molecule drugs used in cancer treatment. TOT BIOPHARM also engages in strategic partnerships and collaborations with other pharmaceutical companies, which can include joint development agreements, licensing, and co-marketing arrangements that provide additional revenue streams. The company's earnings are further supported by its manufacturing capabilities, enabling it to supply products both domestically and internationally, contributing to its overall revenue growth.

TOT BIOPHARM International Co. Ltd. Financial Statement Overview

Summary

TOT BIOPHARM International Co. Ltd. has shown a strong recovery in revenue and profitability with improved margins. The balance sheet is solid with low debt and positive ROE. However, cash flow remains a concern with negative Free Cash Flow, indicating potential liquidity challenges.

Income Statement

The company has shown a significant improvement in revenue and profitability. Gross Profit Margin and Net Profit Margin have improved substantially from negative to positive, indicating a turnaround. The EBIT and EBITDA margins have moved from negative to positive, highlighting improved operational efficiency. However, the company faced challenges in previous years with negative growth, which could indicate potential volatility.

Balance Sheet

The balance sheet is strong with a relatively low Debt-to-Equity Ratio, indicating prudent financial leverage. The Return on Equity has turned positive, suggesting effective use of shareholder funds. The Equity Ratio is stable, showing a solid equity base. The company has maintained a healthy cash position over the years, enhancing financial stability.

Cash Flow

The cash flow statements show some concerns. The Free Cash Flow remains negative, impacting the cash flow score. However, the company has improved its Operating Cash Flow to Net Income Ratio, reflecting better cash generation from operations. Continued negative Free Cash Flow indicates potential liquidity challenges, although the company has managed its financing activities to maintain cash reserves.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.10B	780.63M	442.18M	76.33M	22.49M
	Gross Profit
782.43M	573.99M	370.62M	27.47M	15.53M
	EBIT
41.25M	-33.06M	-39.08M	-259.70M	-288.67M
	EBITDA
84.96M	10.45M	-5.41M	-224.51M	-254.71M
	Net Income Common Stockholders
34.76M	-37.76M	-49.92M	-261.22M	-288.50M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
381.26M	358.36M	458.05M	152.81M	225.53M
	Total Assets
1.51B	1.43B	1.26B	710.26M	641.18M
	Total Debt
395.47M	345.65M	289.53M	208.56M	7.41M
	Net Debt
14.21M	-5.95M	-128.24M	55.76M	-218.13M
	Total Liabilities
779.12M	739.41M	546.59M	375.17M	58.83M
	Stockholders Equity
729.65M	686.69M	713.88M	335.09M	582.36M
Cash Flow		Free Cash Flow
0.00	-146.77M	-180.19M	-290.45M	-285.30M
	Operating Cash Flow
0.00	56.43M	59.93M	-175.14M	-263.12M
	Investing Cash Flow
0.00	-164.10M	-282.76M	-108.39M	12.53M
	Financing Cash Flow
0.00	38.23M	481.24M	212.08M	-61.71M

TOT BIOPHARM International Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Neutral. The current price of 1.91 is below the 20-day moving average (MA) of 1.94, above the 50-day MA of 1.87, and above the 200-day MA of 1.87, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 47.25 is Neutral, neither overbought nor oversold. The STOCH value of 20.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1875.

TOT BIOPHARM International Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	68 Neutral	HK$1.48B	36.94	4.92%	―	38.48%	―
Sector *	51 Neutral	$7.32B	0.30	-60.36%	2.39%	17.47%	1.73%
6622	45 Neutral	HK$1.49B	―	-12.04%	―	260.78%	40.04%
2181	42 Neutral	HK$1.94B	―	-86.56%	―	190.48%	40.11%
6978	37 Underperform	HK$1.58B	―	-228.99%	―	―	44.88%
2511	36 Underperform	HK$1.48B	―	-67.57%	―	―	54.79%
2185	32 Underperform	HK$1.53B	―	-12.49%	―	―	50.94%

TOT BIOPHARM International Co. Ltd. Corporate Events

TOT BIOPHARM Announces Board Committee Changes for Compliance

TOT BIOPHARM International Co. Ltd. has announced a change in the composition of its board committee. Dr. Liu, Weidong, who was previously the chairperson of the Remuneration Committee, has been replaced by Mr. Zhang, Qing, an independent non-executive director, to comply with the Listing Rules of the Hong Kong Stock Exchange. This change is effective from March 21, 2025, and aims to ensure the company meets regulatory requirements, potentially impacting its governance structure and investor confidence.

TOT BIOPHARM Announces Board and Committee Restructuring

TOT BIOPHARM International Co. Ltd. announced changes to its board of directors and committee roles, effective from March 21, 2025. These updates include the appointment of Dr. Liu, Jun as the Executive Director and CEO, and adjustments in committee memberships, which are expected to enhance the company’s governance and strategic direction.

TOT BIOPHARM Announces Board Changes with New Director Appointments

TOT BIOPHARM International Co. Ltd. announced changes in its board of directors and board committees, effective March 12, 2025. Three independent non-executive directors, Ms. Hu Lan, Mr. Chang Hong-Jen, and Dr. Wang De Qian, have resigned due to the expiration of their terms and personal commitments. The company has appointed Ms. Sun Hui, Mr. Zhang Qing, and Dr. Gu Xuelin as new independent non-executive directors, bringing extensive experience in accounting, financial management, and capital markets to the board. These changes are expected to bring fresh perspectives and strengthen the company’s governance as it continues to focus on its strategic goals.

TOT BIOPHARM Announces New Board and Committee Structure

TOT BIOPHARM International Co. Ltd. has announced a new composition for its board of directors and committees, effective from March 12, 2025. The board will include a mix of executive, non-executive, and independent non-executive directors, with specific roles assigned across four key committees: Audit and Connected Transactions Review, Remuneration, Nomination, and Strategy and ESG. This restructuring is likely aimed at strengthening governance and strategic oversight, potentially impacting the company’s operational focus and stakeholder engagement.

TOT BIOPHARM Achieves Profitability and Expands CDMO Projects in 2024

TOT BIOPHARM International Co. Ltd. reported a significant financial turnaround in 2024, achieving a net profit of RMB34,757 thousand, driven by a 41% increase in revenue to over RMB1 billion. The company’s CDMO business showed strong growth potential, securing 58 new projects and enhancing its future revenue expectations, while maintaining high standards of quality management recognized globally.

TOT BIOPHARM to Review Annual Results in March Board Meeting

TOT BIOPHARM International Co. Ltd. has announced that its board of directors will meet on March 11, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.